NEW YORK and TORONTO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to improving
Co-founders to step down from executive roles and continue to serve on the Board of Directors Helus Pharma board member, Mark Lawson, appointed as new independent Chair of the Board of Directors, effective immediately
Topline data readout from APPROACH Phase 3 study of HLP003 in development for the potential adjunctive treatment of major depressive disorder ("MDD") on track for Q4 20261,2 HLP004 Program progressing with
This news release constitutes a "designated news release" for the purpose of the Company’s prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as
NEW YORK and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (NASDAQ:HELP) (Cboe CA: HELP) ("Helus" or the "Company"), a clinical-stage pharmaceutical company committed to helping minds
NEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) ("Helus" or the "Company"), a clinical-stage pharmaceutical company committed to helping minds heal by
TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) ("Helus" or the "Company"), a clinical-stage pharmaceutical company committed to helping minds heal by developing
NEW YORK and TORONTO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to helping minds
Poster presentations further characterize clinical profile of HLP003 and Phase 3 PARADIGM program evaluating HLP003 as a potential adjunctive treatmentfor major depressive disorder ("MDD") NEW YORK and
NEW YORK and TORONTO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to helping minds
NEW YORK and TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to helping minds
NEW YORK and TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to helping minds
Former Intra-Cellular Therapies, Inc. ("Intra-Cellular") executives bring complementary experience in organizational scale-up, central nervous system ("CNS") drug development, regulatory approvals and
- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization - - Completed enrollment in the Phase 3
NEW YORK and TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to helping minds
